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How can we monitor the health of a population?
How can we determine the effects of a specific
disease on that health?
How can we compare the health effects of many
diseases, to determine which should be addressed?
Health is multidimensional, and determining how health is
affected by disease is therefore complex. Answering these
questions requires rigorous research inquiry based on
established techniques in epidemiology, biostatistics, eco-
nomics, psychometrics, and decision analysis. In addition
to their scientific interest and significance to our patients
and practices, these questions are important to the conduct
and goals of our research efforts, and to the public health.
This focused issue of the Journal is devoted to studies
that address the burden of skin diseases. In this commen-
tary, we will provide a conceptual basis for these studies.
We will discuss what is meant by burden of disease, and
propose a taxonomy, or a system to organize the various
components of disease burden. We will identify methodo-
logical difficulties that arise not only in measuring burden of
disease, but also in comparing the burdens of different
diseases. We will describe distinct challenges that face us in
measuring and assessing the significance of the burden of
skin diseases in particular, which generally do not affect
survival or functioning, but which nonetheless can greatly
affect patients’ mood and psychological functioning. We will
end by discussing current metrics for global burden of
disease in populations, suggesting that these commonly
cited measures may be inadequate for assessing the
burden of skin disease.
The interest of the Journal in this topic reflects a
widespread and growing international trend. When we
searched MEDLINE for the term ‘‘burden of disease’’, we
found a dramatic increase over the last 40 y in the number
of papers accessed (Table I). This increase is due to a
powerful confluence of political and academic initiatives.
Scholarly work examining the burden of disease is based on
and parallels long-standing work on cost of illness (Rice
et al, 1985), reflecting a growing scrutiny by governments
and international consortiums in the financial repercussion
of various illnesses. In the early 1990s, the World Bank and
the World Health Organization (WHO) moved beyond
monetary costs only and undertook the Global Burden of
Disease enterprise to learn about the contribution of
different diseases to ill-health (Murray and Lopez, 1997).
In the mid-1990s the Institute of Medicine proposed that
disease-specific research funding by the National Institutes
of Health be compared with the burden of specific diseases
or disease groups on which the individual Institutes focus
(Gross et al, 1999). Thus, there were strong scholarly and
financial incentives to measure the burden of diseases.
Deﬁning Burden of Disease
For the purposes of this commentary, we define burden of
disease as the effects of disease on overall health. The
burden of disease cannot be adequately expressed as
a single number. Traditional measures of mortality and
incidence are important, but provide an incomplete picture.
For example, the impact of disease on quality of life and
ability to function are not reflected in the incidence and
mortality numbers. As with diseases of many organ
systems, the burden of skin diseases can be assessed
from the viewpoints of the person, the family, and society.
Atopic dermatitis illustrates these multiple perspectives.
Atopic dermatitis is a common childhood chronic disease,
affecting 5%–10% of children (Kemp, 1999), and causing
broad and significant effects on the well-being and
development of afflicted children (Lawson et al, 1998). In
addition, families of children with moderate or severe atopic
dermatitis reported significantly higher effects of the child’s
eczema on the family’s economic and psycho-social well-
being than did families of children with diabetes (Su et al,
1997). Also, atopic dermatitis is a financially costly disease
for society (Kemp, 1999). Thus, multiple perspectives of the
burden of atopic dermatitis can be measured accurately,
and compared informatively with those of other conditions.
A Taxonomy of Burden of Disease
A practical conceptual framework for the components of
burden of disease is presented in Fig 1. Components of
burden of disease can be either economic or non-
economic. Economic burdens include costs that are direct
(i.e., for which funds can be paid, such as health services
used), or indirect (i.e., for which charges are not routinely
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assigned, such as lost income due to disability or pre-
mature death). Non-economic burdens are the effects of a
given disease on survival, and on the well-being of the
population. The effects of a disease on an individual’s well-
being can be conceived as related to the impairment,
disability, or handicap caused by the disease (Patrick,
1994). Using WHO terminology, impairment refers to the
biological properties of the disease (e.g., the degree of
scaling caused by psoriasis). Disability refers to diminished
functioning caused by disease (e.g., inability to use one’s
hand because of psoriasis involving the palms). Handicap
refers to the effects of the disease on one’s overall quality of
life.
Methodological Issues in Measuring
Burden of Disease
Measurement schemes and tools have been developed for
each of these components of burden of disease. Economic
aspects are usually measured in money spent or in
resources utilized. Simple counting of the number of cases
of a disease is an important early step in assessing burden,
and can be expressed as incidence (number of new cases,
typically expressed as a ratio to the size of the population at
risk) or prevalence (the proportion of the population that is
affected). Death is a catastrophic consequence of disease,
and is measured primarily by mortality rate. These rates are
typically age adjusted to a standard population; hence, if
inferences are to be drawn from the relative magnitudes of
mortality rates, the standard used for age adjustment must
be specified to avoid misleading conclusions. For example,
the 1998 mortality from melanoma in the United States
(per 100,000 per y) was 4.1 and 1.8 for men and women,
respectively, when the 2000 USA standard was used, but
only 2.7 and 1.2 when the 1940 USA standard population
was used. Misleading inferences can also result from
uncritical acceptance of government statistics without
evidence of accuracy of those numbers. Examples include
data about non-melanoma skin cancer and cutaneous
lymphoma, which have been shown to have large inac-
curacies (Weinstock et al, 1992; Weinstock and Reynes,
1998). Another measure related to mortality rate is ‘‘years of
life lost’’. Here care must be taken to scrutinize the method
by which this is calculated, since the use of different
methods can mislead (Weinstock, 1993).
Since most skin diseases are not associated with
substantial mortality, measures of morbidity assume greater
importance for measurement of burden of disease (Wein-
stock and Chren, 2003). Well-being, however, is not easily
‘‘counted’’. Because the components of well-being are
either clinical phenomena (e.g., extent of disease) or
abstract concepts (e.g., quality of life), precise measure-
ment has required the application of scientific measurement
principles from clinimetrics (Feinstein, 1987) and psycho-
metrics. These techniques have been used to design
disease severity measures (to assess impairment), disability
measures (to assess diminished functioning), and quality-
of-life instruments (to assess handicap). Because dermato-
logical diseases only uncommonly affect laboratory values,
measures of disease severity typically involve clinician
ratings of the clinical characteristics of disease, such as
degrees of scaling, or extent of body surface area involved.
Disability measures determine patients’ ability to perform
certain functions, either by direct observation of the
performance, or by report. Quality-of-life measures assess
patients’ experiences and perceptions of disease, and
therefore consist of questionnaires in which patients
respond to items that inquire about aspects of quality of
life, such as symptoms, functioning, and psychological
state. Responses to items are typically assigned numeric
values; total scores are calculated based on the responses
to the items, and are most often reported as a profile of
subscores corresponding to the various aspects of quality
of life.
Some measures of well-being are intended to measure
the value a person attaches to life with a disease, assessing
patients’ (or peoples’) preferences for different health
states. One example of these preference measures is
utilities; utilities are typically measured by determining
respondents’ willingness to trade off time lived with a
disease for disease-free life, or their willingness to pay to
avoid having a disease. One advantage of utilities is their
interpretability: regardless of disease, they are generally
reported on a 0 (death)–1.0 (healthy life) scale. Also,
because utilities are reported as single scores (rather than
a profile of scores), they are useful for cost-effectiveness
studies in which single-metric quality-of-life scores are
needed. Utilities can be difficult and time-consuming to
elicit, however, and their validity has been questioned
(Giesler et al, 1999). Other examples of value-adjusted
metrics include health-adjusted life years and disability-
adjusted life years. How the ‘‘value’’ is determined, whose
responses are being assessed, and how the adjustment for
value is made have important implications for assessing the
effects on well-being of different diseases (Cohen, 2000).
Table I. Number of citations in PubMed for search term
‘‘burden of disease’’, by decade
Year Number of citations
1961–1970 0
1971–1980 4
1981–1990 12
1991–2000 284
Figure 1
Taxonomy for burden of disease.
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Challenges in Measuring Burden of Disease
Measuring complex aspects of health is challenging. As
with all measurement tools, instruments to assess
the components of burden of disease must at a minimum
be reliable (i.e., have a high signal-to-noise ratio) and valid
(i.e., measure what they are intended to measure) (Chren,
2000).
In addition, we face unique challenges in attempting to
describe and measure the burden of skin disease. First, the
term ‘‘skin disease’’ is ambiguous, both with respect to the
term ‘‘skin’’ and the term ‘‘disease.’’ Biological conditions
often involve multiple organ systems, and there may be no
consensus on whether they primarily or predominantly
concern the skin. For example, thermal burns, decubiti,
and melanoma are common conditions often treated
primarily by surgeons or oncologists rather than dermatol-
ogists, and, when they lead to death, it is because of their
effect on other organ systems. Lupus is an example of a
disease that may be exclusively cutaneous or have no
cutaneous manifestations. Further, there is disagreement
about whether certain conditions (e.g., skin aging, striae,
male-pattern baldness, ‘‘oily’’ facial skin) should be con-
sidered diseases at all, and whether the consequences of
undesirable manifestations of what is arguably normal
variation in the human condition should be counted in the
burden of disease. Some of the disagreement relates to
who is participating in the debate. A substantial portion of
lay people, for example, do not regard acne vulgaris as a
disease at all (Smith, 2002).
A second challenge is the fact that many skin diseases
are chronic, and their burden is experienced more in living
with the disease, than in dying from it. Thus, as with all
chronic diseases, accurate measures of well-being are
especially important for comprehensive assessments of
burden of skin diseases. These measures—of impairment,
disability, and handicap—can be difficult to develop,
administer, and interpret, compared with more straightfor-
ward measures of incidence and mortality.
A third challenge relates to the complex relationship
(especially for skin diseases) among impairment, disability,
and handicap. For many—if not most—clinical conditions
(Nease et al, 1995; Nichol et al, 1996), the severity of the
impairment, or biological properties of the disease (e.g., the
degree of coronary artery occlusion or of palmar hyperker-
atosis) does not correlate in a predictable, linear fashion
with the disability of the patient (e.g., the inability to run
without angina or to use one’s hands easily). Likewise, a
degree of disability does not always handicap patients in
the same way (e.g., a sedentary patient may not care to run,
or a pianist may be devastated by being unable to use her
hands). The complexity of this relationship, although true for
most diseases, is perhaps most pronounced for skin
diseases, which, because they can affect appearance
and self-esteem, may handicap more than they impair or
physically disable. Thus, a comprehensive assessment of
skin disease burden requires a formal and explicit assess-
ment of handicap. Such an assessment requires input from
patients themselves, for clinicians are not able to predict
accurately the quality of life effects of their patients’
conditions (Parkerson et al, 1992).
State-of-the-art in Assessing Burden of
Skin Disease
The papers in this focus issue of the Journal represent many
approaches to measuring components of the burden of skin
disease. The commentary by Karl Holubar provides a
philosophical perspective [Holubar 0282], and Marie-Louise
Johnson describes the seminal work she spearheaded on
determining the prevalence of skin diseases by actual
examinations performed as part of the first US Health and
Nutrition Examining Survey of 1971–1974 [Johnson 0370]. A
profile of current care for skin diseases in the US is provided
by Robert Stern’s analysis of data from the National
Ambulatory Medical Care Survey [Stern 0291]. The difficul-
ties of measurement of even the most straightforward
assessments are illustrated by Valery and colleagues’
documentation of the effect of examinations on the
measured incidence rate of basal cell carcinoma [Valery
0332]. A population-based assessment of skin-related
symptoms and effects on well-being is reported [Dalgard
0321], and additional papers describe measurement tools
for aspects of well-being in dermatology patients, including
quality of life [Lewis 0331], and utilities [Soon 0330]. Other
papers address how well-being is affected by specific skin
conditions [Stern 0266, de Korte 0313, Bishop 0293],
including the relationship in patients with psoriasis between
quality of life and clinical measures of disease severity
[Heydendael 0333, Sampogna 0620].
Overall, these works represent significant progress by
dermatologic researchers in conceptualizing and measuring
burden of skin disease. The plethora of measurement tools
illustrates in part the complexity and challenges inherent in
measuring burden of skin disease that we describe above.
Taken together, the papers describe a sequence of
gathered evidence about skin disease burden, rather than
a single metric or a single result. There is great interest in
global metrics, however, given the national and international
political and financial interest in the results of studies of
burden of disease. Single numeric results are seductively
‘‘easy’’ to report and translate and seem—at least on the
surface—straightforward and highly practical for making
comparisons among burdens caused by different diseases.
Given the multidimensional nature of the impacts of disease
this apparent simplicity can be deceptive, and given the
potential power of these measures, it is important for us to
understand how the measures are designed and studied
before accepting their results at face value (Nygaard, 2000).
A typical example of such a ‘‘summary’’ measure of burden
of disease is the Disability-Adjusted Life Year (DALY), the
overall burden index used by the Global Burden of Disease
study (Murray and Lopez, 1997). The DALY represents a
method to quantify the health consequences of the years of
life lived with a disability. It is a disability index that, for a
given condition, reflects the probability of progressing to a
disability, the duration of life lived with the disability, and the
‘‘value’’ of the disability (i.e., its severity in terms of activity
restriction) (Cohen, 2000). Note that this measure of disease
burden focuses exclusively on disability as the way a
disease affects well-being. As we discussed above,
accurate measures of the burden of skin diseases must
assess not only disability but also handicap, or the effects of
BURDEN OF SKIN DISEASES 999 : 2 MARCH 2004
a disease on patients’ quality of life. Moreover, for the
determination of disabilities related to different diseases,
the Global Burden of Disease study used a panel of experts,
who reviewed and compared disabilities related to the
diseases in question, and rank-ordered them. As we
discussed above, expert ratings may not correlate with
ratings made by persons suffering from a disease (or even
the general public).
The issues we have raised in this commentary should
guide any consideration for the use of existing summary
measures (such as DALY) for the assessment of the burden
of skin diseases. In evaluating global measures we should
ask Were important components of disease burden
adequate considered? For example, the DALY measures
disability only, not handicap. Measuring only the extent to
which activity is restricted by a disease (disability) ignores a
significant type of burden a disease can impose, namely,
the effects of a disease on other aspects of quality of life
such as psychological and social functioning. This oversight
may particularly underestimate the burden of skin diseases,
because of their frequent effects on these aspects of well-
being. Second, How was ‘‘severity’’ of burden weighted? As
we have noted, patients vary greatly in how they value
health states, and experts may not accurately assess the
experience of patients with a disease. Finally, we need to
keep in mind that estimates of disease burden can vary
substantially, depending on which summary measure is
used (Gold and Muennig, 2002).
Conclusion
It seems likely that national and global efforts to monitor
and compare overall health and individual diseases will
increase. We in dermatology need to articulate important
features about the burden of skin diseases, and promote
rigorous scientific approaches to measuring this burden. It
is clear that the burden of skin diseases can and should be
assessed from multiple perspectives, including that of the
patient, family, and society. Burden includes both economic
and non-economic aspects, and a comprehensive assess-
ment will require measurement of incidence and mortality as
well as other dimensions of health, including patients’
reports of disability and handicap.
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